Results 21 to 30 of about 82,539 (194)

Assessment of the influence of the inflammatory process on the activation of blood platelets and morphological parameters in patients with ulcerative colitis (<i>colitis ulcerosa</i>)

Folia Histochemica et Cytobiologica, 2011
Ulcerative colitis (<i>colitis ulcerosa</i>) is a non-specific inflammatory bowel disease of unknown etiology. The symptoms which are observed in the course of ulcerative colitis are: an increase in the number of leukocytes and blood ...
Halina Kemona, Joanna Matowicka-Karna, Beata Polińska   +2 more
doaj   +1 more source

Untersuchung von Anti‐Glykan‐Antikörpern und Erforschung ihres medizinischen Potenzials mithilfe synthetischer Glykane

Angewandte Chemie, Volume 138, Issue 39, 21 September 2026.
Anti‐Glykan‐Antikörper spielen sowohl bei Gesundheit als auch bei Krankheit eine wesentliche Rolle. Der Zugang zu neuartigen Glykanstrukturen ermöglicht Fortschritte bei der Antikörpercharakterisierung für die Entdeckung von Biomarkern, die Antikörperentwicklung und das Impfstoffdesign.
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Therapie der Colitis ulcerosa

, 2009
Die Therapie der Colitis ulcerosa richtet sich nach der Krankheitsaktivität vergleichbar mit dem Morbus Crohn aber auch nach der Ausdehnung der Erkrankung. Unterschiedliche Therapiekonzepte kommen dabei zur Anwendung je nachdem ob die Colitis ulcerosa in
Rogler, G, Vavricka, S R
core   +1 more source

The History of the Discovery of Vitamin K

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 3, September 2026.
ABSTRACT Vitamin K was discovered during the 1930s when a strange haemorrhagic disorder was observed in chickens fed a cholesterol‐free diet. A fat‐soluble agent, present in green leafy vegetables and hog liver, was able to restore haemostasis in the chickens.
Hanna Nørgaard Tuxen, Laila Zwisler, Allan Linneberg   +2 more
wiley   +1 more source

TRATAMIENTO QUIRÚRGICO DE LA COLITIS ULCEROSA

Revista Médica Clínica Las Condes, 2019
Resumen: El tratamiento médico de pacientes con colitis ulcerosa se basa en aminosalicilatos, corticoides, inmunomoduladores y en los últimos años en terapia biológica predominantemente con anti-TNF.
Udo Kronberg
doaj   +1 more source

A gyulladásos bélbetegségek gyógyszeres kezelése: Colitis ulcerosa

, 2007
A colitis ulcerosa kezelésében kevesebb a változás, mint a Crohn-betegségben. A betegek nagy többsége ma is a hagyományos gyógyszereket kapja. A kezelést meghatározó legfontosabb tényezők a betegség kiterjedése és súlyossága.
Péter László Lakatos, László Lakatos, Lakatos, Péter László, Lakatos, László   +3 more
core   +1 more source

Impacto del cigarrillo en el tracto gastrointestinal: Efecto diferencial en Enfermedad de Crohn y Colitis Ulcerosa

ARS Medica, 2017
El impacto del consumo de cigarrillo a nivel respiratorio y cardiovascular ha sido extensamente investigado, sin embargo, aún queda mucho por estudiar sobre su impacto en el tracto gastrointestinal.
Loni Berkowitz Fiebich, Manuel Álvarez Lobos   +1 more
doaj   +1 more source

Epidemiología, carga de la enfermedad y tendencias de tratamiento de la enfermedad inflamatoria intestinal en México

Revista de Gastroenterología de México, 2020
Resumen: Introducción y objetivos: En México no existe información sistematizada para determinar/monitorizar la carga de la enfermedad inflamatoria intestinal (EII).
J.K. Yamamoto-Furusho, F.J. Bosques-Padilla, L. Charúa-Guindic, T. Cortés-Espinosa, R.M. Miranda-Cordero, A. Saez, Y. Ledesma-Osorio   +6 more
doaj   +1 more source

Adaptation of the International Consortium for Health Outcomes Measurement Standard Set for Inflammatory Bowel Disease for Routine Collection in Clinical Practice

JCC Plus, Volume 1, Issue 4, July 2026.
ABSTRACT Background and Aims Value‐based healthcare (VBHC) is based on evaluating clinical interventions according to their ability to improve outcomes and costs to finally enhance quality of care. As part of an initiative to introduce VBHC in inflammatory bowel disease (IBD), our project aimed to adapt the International Consortium for Health Outcomes ...
Xavier Calvet, Iago Rodríguez‐Lago, Jose‐Lázaro Pérez‐Calle, Hugo Bronchalo‐Bautista, Elena Barbazán‐García, on behalf of the EEImprove Collaborative Project TEam, Alberto Vegas‐Miguel, Alicia Diaz‐Redondo, Ane Fullaondo‐Zabala, Carles Illa, Celia Albaladejo Blanco, Daniel Ceballos, Ignacio Marín‐Jiménez, Jesus Barrio Andres, Jesús Gonzalo Gómez Gómez, Jone Ortiz de Zaarate Sagastagoitia, Juan Manuel Sánchez Lledó, Laura Gómez‐Irwin, Luis Alberto Menchen Viso, Maite Zabala Ugarteburu, María Carme Nicolás Herrerías, María Dolores Martín‐Arranza, María Esteve Comas, María Mercedes Ortiz Otero, Mirari San Felix Carrasco, Mónica Sierra‐Ausin, Monsterrat Aceituno Quintanilla, Olga Merino Ochoa, Pilar López Serrano, Raúl Martín Puentes, San José Fernando Bermejo, Susana Castelo Zas, Susana Lorenzo Martínez, Yamile Zabana   +33 more
wiley   +1 more source

Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register‐Based Time Series Analysis

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Purpose Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis.
Jarno Rutanen, Pekka Heino, Kati Sarnola, Terhi Kurko   +3 more
wiley   +1 more source